Mereo BioPharma (MREO) Cash from Investing Activities (2023 - 2026)
Mereo BioPharma (MREO) posted quarterly Cash from Investing Activities of -$300000.0 for Q1 2026, up 6.25% year-over-year from -$282352.9 in Q1 2025, and down 200.0% quarter-over-quarter from $300000.0 in Q3 2025.
Mereo BioPharma (MREO) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Cash from Investing Activities for 4 consecutive years, with -$300000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 6.25% year-over-year to -$300000.0; the TTM figure through Dec 2025 stood at -$20000.0 (up 97.14% YoY), while the FY2025 annual figure was -$20000.0, up 97.14% from the prior year.
- Cash from Investing Activities retreated to -$300000.0 in Q1 2026 per MREO's latest filing, from $300000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $300000.0 in Q3 2025 and bottomed at -$700000.0 in Q1 2024.
- Historically, Cash from Investing Activities has averaged -$239666.7 across 4 years, with a median of -$310000.0 in 2025.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities plunged 67.06% — and 2025, when it surged 54.29%.
- Mereo BioPharma's Cash from Investing Activities stood at -$419000.0 in 2023, then soared by 100.24% to $1000.0 in 2024, then soared by 29900.0% to $300000.0 in 2025, then slumped by 200.0% to -$300000.0 in 2026.
- Business Quant data shows MREO's Cash from Investing Activities at -$300000.0 in Q1 2026, $300000.0 in Q3 2025, and -$320000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -300,000.00 |
| Mar 31, 2026 | -300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Mar 31, 2025 | -320,000.00 |
| Mar 31, 2025 | -320,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | -700,000.00 |
| Mar 31, 2024 | -700,000.00 |
| Mar 31, 2023 | -419,000.00 |
| Mar 31, 2023 | -419,000.00 |